ACOR Acorda Therapeutics Inc.

2.7
+0.08  (+3%)
Previous Close 2.62
Open 2.61
Price To Book 0.24
Market Cap 129,891,659
Shares 48,108,022
Volume 2,657,994
Short Ratio
Av. Daily Volume 1,357,749

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.
Ampyra
Improve walking in patients with multiple sclerosis
Phase 1 complete. Noted November 2017 that it will not advance into a Phase 2 study by the end of 2017, as previously expected. Evaluating next steps.
CVT-427
Migraine
Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued.
Tozadenant
Parkinson’s disease (PD)
Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.
Dalfampridine
Post stroke deficits
FDA Approval announced December 22, 2018.
INBRIJA (CVT-301)
OFF episodes of Parkinson’s disease (PD)
Phase 2 interim data were slated for 3Q 2018 - no update given to date from company.
BTT1023
Primary Sclerosing Cholangitis